vs
Avantor, Inc.（AVTR）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是STANDARD BIOTOOLS INC.的516.3倍（$1.7B vs $3.2M）。STANDARD BIOTOOLS INC.净利率更高（598.5% vs 3.1%，领先595.3%）。STANDARD BIOTOOLS INC.同比增速更快（262.0% vs -1.4%）。Avantor, Inc.自由现金流更多（$117.2M vs $-1.7M）。过去两年Avantor, Inc.的营收复合增速更高（-0.5% vs -73.4%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
AVTR vs LAB — 直观对比
营收规模更大
AVTR
是对方的516.3倍
$3.2M
营收增速更快
LAB
高出263.4%
-1.4%
净利率更高
LAB
高出595.3%
3.1%
自由现金流更多
AVTR
多$118.9M
$-1.7M
两年增速更快
AVTR
近两年复合增速
-73.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $3.2M |
| 净利润 | $52.4M | $19.3M |
| 毛利率 | 31.5% | 83.5% |
| 营业利润率 | 7.6% | -578.6% |
| 净利率 | 3.1% | 598.5% |
| 营收同比 | -1.4% | 262.0% |
| 净利润同比 | -89.5% | 156.6% |
| 每股收益（稀释后） | $0.08 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRLAB
| Q4 25 | $1.7B | $3.2M | ||
| Q3 25 | $1.6B | $19.6M | ||
| Q2 25 | $1.7B | $21.8M | ||
| Q1 25 | $1.6B | $40.8M | ||
| Q4 24 | $1.7B | $890.0K | ||
| Q3 24 | $1.7B | $22.1M | ||
| Q2 24 | $1.7B | $22.5M | ||
| Q1 24 | $1.7B | $45.5M |
净利润AVTRLAB
| Q4 25 | $52.4M | $19.3M | ||
| Q3 25 | $-711.8M | $-34.7M | ||
| Q2 25 | $64.7M | $-33.5M | ||
| Q1 25 | $64.5M | $-26.0M | ||
| Q4 24 | $500.4M | $-34.1M | ||
| Q3 24 | $57.8M | $-26.9M | ||
| Q2 24 | $92.9M | $-45.7M | ||
| Q1 24 | $60.4M | $-32.2M |
毛利率AVTRLAB
| Q4 25 | 31.5% | 83.5% | ||
| Q3 25 | 32.4% | 48.5% | ||
| Q2 25 | 32.9% | 48.8% | ||
| Q1 25 | 33.8% | 48.4% | ||
| Q4 24 | 33.4% | -202.8% | ||
| Q3 24 | 32.9% | 54.9% | ||
| Q2 24 | 34.1% | 46.1% | ||
| Q1 24 | 34.0% | 53.1% |
营业利润率AVTRLAB
| Q4 25 | 7.6% | -578.6% | ||
| Q3 25 | -40.0% | -168.5% | ||
| Q2 25 | 7.7% | -118.1% | ||
| Q1 25 | 9.3% | -80.8% | ||
| Q4 24 | 37.8% | -1162.1% | ||
| Q3 24 | 7.3% | -120.9% | ||
| Q2 24 | 10.3% | -134.5% | ||
| Q1 24 | 8.7% | -132.2% |
净利率AVTRLAB
| Q4 25 | 3.1% | 598.5% | ||
| Q3 25 | -43.8% | -177.4% | ||
| Q2 25 | 3.8% | -153.7% | ||
| Q1 25 | 4.1% | -63.8% | ||
| Q4 24 | 29.7% | -3828.3% | ||
| Q3 24 | 3.4% | -122.0% | ||
| Q2 24 | 5.5% | -203.3% | ||
| Q1 24 | 3.6% | -70.6% |
每股收益（稀释后）AVTRLAB
| Q4 25 | $0.08 | $0.05 | ||
| Q3 25 | $-1.04 | $-0.09 | ||
| Q2 25 | $0.09 | $-0.09 | ||
| Q1 25 | $0.09 | $-0.07 | ||
| Q4 24 | $0.73 | $-0.06 | ||
| Q3 24 | $0.08 | $-0.07 | ||
| Q2 24 | $0.14 | $-0.12 | ||
| Q1 24 | $0.09 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $120.9M |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $5.6B | $424.3M |
| 总资产 | $11.8B | $567.8M |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资AVTRLAB
| Q4 25 | $365.4M | $120.9M | ||
| Q3 25 | $251.9M | $129.4M | ||
| Q2 25 | $449.4M | $158.6M | ||
| Q1 25 | $315.7M | $150.9M | ||
| Q4 24 | $261.9M | $166.7M | ||
| Q3 24 | $285.3M | $210.6M | ||
| Q2 24 | $272.6M | $269.8M | ||
| Q1 24 | $234.9M | $287.1M |
总债务AVTRLAB
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | $299.0K | ||
| Q3 24 | $4.9B | $55.2M | ||
| Q2 24 | $5.1B | $55.1M | ||
| Q1 24 | $5.3B | $55.0M |
股东权益AVTRLAB
| Q4 25 | $5.6B | $424.3M | ||
| Q3 25 | $5.6B | $399.7M | ||
| Q2 25 | $6.3B | $424.5M | ||
| Q1 25 | $6.1B | $454.6M | ||
| Q4 24 | $6.0B | $471.7M | ||
| Q3 24 | $5.6B | $489.3M | ||
| Q2 24 | $5.4B | $510.3M | ||
| Q1 24 | $5.3B | $577.3M |
总资产AVTRLAB
| Q4 25 | $11.8B | $567.8M | ||
| Q3 25 | $11.7B | $539.6M | ||
| Q2 25 | $12.8B | $557.0M | ||
| Q1 25 | $12.3B | $579.6M | ||
| Q4 24 | $12.1B | $612.3M | ||
| Q3 24 | $12.8B | $681.5M | ||
| Q2 24 | $12.7B | $708.7M | ||
| Q1 24 | $12.8B | $777.7M |
负债/权益比AVTRLAB
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | 0.00× | ||
| Q3 24 | 0.89× | 0.11× | ||
| Q2 24 | 0.94× | 0.11× | ||
| Q1 24 | 1.00× | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $-1.7M |
| 自由现金流率自由现金流/营收 | 7.0% | -51.7% |
| 资本支出强度资本支出/营收 | 2.1% | 14.8% |
| 现金转化率经营现金流/净利润 | 2.91× | -0.06× |
| 过去12个月自由现金流最近4个季度 | $495.0M | $-82.6M |
8季度趋势，按日历期对齐
经营现金流AVTRLAB
| Q4 25 | $152.7M | $-1.2M | ||
| Q3 25 | $207.4M | $-22.2M | ||
| Q2 25 | $154.4M | $-20.7M | ||
| Q1 25 | $109.3M | $-30.3M | ||
| Q4 24 | $173.3M | $-14.1M | ||
| Q3 24 | $244.8M | $-27.9M | ||
| Q2 24 | $281.1M | $-39.0M | ||
| Q1 24 | $141.6M | $-62.5M |
自由现金流AVTRLAB
| Q4 25 | $117.2M | $-1.7M | ||
| Q3 25 | $171.7M | $-23.1M | ||
| Q2 25 | $124.8M | $-22.6M | ||
| Q1 25 | $81.3M | $-35.3M | ||
| Q4 24 | $145.8M | $-17.4M | ||
| Q3 24 | $204.0M | $-30.1M | ||
| Q2 24 | $235.3M | $-41.0M | ||
| Q1 24 | $106.9M | $-63.3M |
自由现金流率AVTRLAB
| Q4 25 | 7.0% | -51.7% | ||
| Q3 25 | 10.6% | -118.1% | ||
| Q2 25 | 7.4% | -103.6% | ||
| Q1 25 | 5.1% | -86.6% | ||
| Q4 24 | 8.6% | -1959.7% | ||
| Q3 24 | 11.9% | -136.4% | ||
| Q2 24 | 13.8% | -182.2% | ||
| Q1 24 | 6.4% | -138.9% |
资本支出强度AVTRLAB
| Q4 25 | 2.1% | 14.8% | ||
| Q3 25 | 2.2% | 4.5% | ||
| Q2 25 | 1.8% | 8.7% | ||
| Q1 25 | 1.8% | 12.4% | ||
| Q4 24 | 1.6% | 380.0% | ||
| Q3 24 | 2.4% | 10.2% | ||
| Q2 24 | 2.7% | 8.6% | ||
| Q1 24 | 2.1% | 1.7% |
现金转化率AVTRLAB
| Q4 25 | 2.91× | -0.06× | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 4.24× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
LAB
暂无分部数据
